Beeram S, Zheng X, Suh K, Hage D
Methods. 2018; 146:46-57.
PMID: 29510250
PMC: 6098730.
DOI: 10.1016/j.ymeth.2018.02.021.
Jackson A, Anguizola J, Pfaunmiller E, Hage D
Anal Bioanal Chem. 2013; 405(17):5833-41.
PMID: 23657448
PMC: 3696424.
DOI: 10.1007/s00216-013-6981-3.
Basken N, Mathias C, Green M
J Pharm Sci. 2008; 98(6):2170-9.
PMID: 18937368
PMC: 2674521.
DOI: 10.1002/jps.21570.
Lapicque F, Muller N, Payan E, Dubois N, Netter P
Clin Pharmacokinet. 1993; 25(2):115-23.
PMID: 8403735
DOI: 10.2165/00003088-199325020-00004.
Paubel J, Niviere P, Payard M, Rabadeux J, Pinazzi C
Eur J Drug Metab Pharmacokinet. 1981; 6(4):241-8.
PMID: 7333323
DOI: 10.1007/BF03189520.
Pharmacokinetics of the enantiomers of acenocoumarol in man.
Godbillon J, Richard J, Gerardin A, Meinertz T, Kasper W, Jahnchen E
Br J Clin Pharmacol. 1981; 12(5):621-9.
PMID: 7332726
PMC: 1401957.
DOI: 10.1111/j.1365-2125.1981.tb01280.x.
Protein binding displacement interactions and their clinical importance.
McElnay J, DArcy P
Drugs. 1983; 25(5):495-513.
PMID: 6345130
DOI: 10.2165/00003495-198325050-00003.
Binding of certain acidic drugs to human albumin: theoretical and practical estimation of fundamental parameters.
Tillement J, Zini R, Athis P, Vassent G
Eur J Clin Pharmacol. 1974; 7(4):307-13.
PMID: 4850753
DOI: 10.1007/BF00560349.
Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone.
Lewis R, TRAGER W, Chan K, Breckenridge A, Orme M, Roland M
J Clin Invest. 1974; 53(6):1607-17.
PMID: 4830225
PMC: 302656.
DOI: 10.1172/JCI107711.
Effect of phenylbutazone on the binding of vitamin K antagonists to albumin.
Tillement J, Zini R, Mattei C, Singlas E
Eur J Clin Pharmacol. 1973; 6(1):15-8.
PMID: 4764367
DOI: 10.1007/BF00561795.
Pharmacokinetics of the warfarin enantiomers in rats.
Yacobi A, Levy G
J Pharmacokinet Biopharm. 1974; 2(3):239-55.
PMID: 4452939
DOI: 10.1007/BF01059764.
Displacement of phenprocoumon (Marcumar) from albumin by sulfonylurea compounds, suramin, and ioglycamic acid.
Huthwohl B, Jahnchen E
Naunyn Schmiedebergs Arch Pharmacol. 1972; 273(3):204-12.
PMID: 4261772
DOI: 10.1007/BF00501412.
Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.
Lin J, Cocchetto D, DUGGAN D
Clin Pharmacokinet. 1987; 12(6):402-32.
PMID: 3301150
DOI: 10.2165/00003088-198712060-00002.
Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy.
Shetty H, Fennerty A, Routledge P
Clin Pharmacokinet. 1989; 16(4):238-53.
PMID: 2656051
DOI: 10.2165/00003088-198916040-00003.
The action of the benzopyrones on an experimental model of lymphoedema: a contribution to their mode of action.
Piller N
Br J Exp Pathol. 1976; 57(6):713-21.
PMID: 1009001
PMC: 2041236.
A comparison of the effect of benzopyrones and other drugs with anti-inflammatory properties on acid and neutral protease activity levels in various tissues after thermal injury.
Piller N
Br J Exp Pathol. 1976; 57(4):411-8.
PMID: 986829
PMC: 2041167.
Interaction of clofibrate with warfarin. I. Effect of clofibrate on the disposition of the optical enantiomorphs of warfarin.
Bjornsson T, Meffin P, Blaschke T
J Pharmacokinet Biopharm. 1977; 5(5):495-505.
PMID: 925883
DOI: 10.1007/BF01061730.
Protein binding of warfarin enantiomers in serum of humans and rats.
Yacobi A, Levy G
J Pharmacokinet Biopharm. 1977; 5(2):123-31.
PMID: 859099
DOI: 10.1007/BF01066216.
Tissue levels of (3(-14)C) coumarin in the rat: distribution and excretion.
Piller N
Br J Exp Pathol. 1977; 58(1):28-34.
PMID: 836764
PMC: 2041195.
Clinical pharmacokinetics of oral anticoagulants.
Kelly J, OMalley K
Clin Pharmacokinet. 1979; 4(1):1-15.
PMID: 369763
DOI: 10.2165/00003088-197904010-00001.
